FESOTERODINE ZENTIVA LP 8 mg, extended-release tablet 30 tablets
Active ingredients: Fesoterodine fumarate, FÉSOTÉRODINE
Commercialized according to BDPMDispensing in France: Prescription only
Extended-release tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- FESOTERODINE ZENTIVA LP 8 mg, comprimé à libération prolongée
- Pharmaceutical form
- comprimé à libération prolongée
- Route of administration
- orale
- Presentation description
- plaquette(s) OPA : polyamide orienté aluminium PVC-Aluminium de 30 comprimé(s)
- Marketing authorisation holder
- ZENTIVA FRANCE
- Reimbursement according to BDPM
- 30 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 28 Apr 2022
- Prescription and dispensing conditions
- Prescription only
- List II: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61458973CIP73022762CIP133400930227626Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| FUMARATE DE FÉSOTÉRODINEcomprimé | 8 mg · un comprimé | SA |
| FÉSOTÉRODINEcomprimé | 6,20 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.